# About Ipamorelin Medicinal — An Independent Research Literature Digest

> Ipamorelin Medicinal is an independent editorial project that publishes summaries of the peer-reviewed research literature on Ipamorelin. We are not a clinic, not a vendor, not a prescriber.

## What Ipamorelin Medicinal Is

Ipamorelin Medicinal is an independent editorial project that publishes summaries of the peer-reviewed research literature on Ipamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The domain modifier "medicinal" is editorial framing — positioning this site as a medicinal chemistry and pharmacology reference document, not as a claim about services offered. The site presents published research the way a technical digest presents primary literature: findings summarized, doses attributed to species and study, citations numbered and linked.

Ipamorelin (NNC 26-0161) is not FDA-approved for any human indication. The FDA Pharmacy Compounding Advisory Committee voted against adding ipamorelin acetate to the 503A bulk drug substances list in October 2024 [16]. Ipamorelin is prohibited under WADA S2 at all times [9]. This site documents the research record — it does not promote, recommend, or facilitate access to the compound.

## Editorial Standards

Every quantitative claim on this site is cited to a numbered reference in the references list. Citations are drawn exclusively from PubMed-indexed publications, ClinicalTrials.gov records, FDA official documents, and peer-reviewed journal sources. No citation is invented; no claim is made without a documented source in the primary literature.

The voice is technical-trust: spare, precise, study-attributed. Findings are stated as findings of the cited study. Limitations are stated where the research record states them: ipamorelin's foundational literature is primarily rodent models at relatively small n; human extrapolation requires significant caution; no large-scale longitudinal safety data in humans exists.

No medical advice is dispensed on any page. No dose recommendation for human use is made anywhere on this site.

## About the Compound Documented Here

Ipamorelin is a five-amino-acid peptide (pentapeptide: Aib-His-D-2-Nal-D-Phe-Lys-NH₂) synthesized by Novo Nordisk under the designation NNC 26-0161. It was designated "the first selective growth hormone secretagogue" by Raun et al. in 1998 [1], a classification that has remained in the literature since. The compound binds GHS-R1a (the ghrelin receptor) on anterior pituitary somatotrophs to produce discrete, bounded GH pulses without elevating cortisol, ACTH, prolactin, or gonadotropins at studied doses [1].

PubMed indexes more than 150 publications related to ipamorelin. The majority are preclinical rodent models. Human data is sparse: the most advanced human investigation is the Phase 2 clinical trial for postoperative ileus (NCT00672074), which completed without an NDA submission [15].

## References

[1] Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
[9] Semenistaya E, et al. GHRP metabolites in human urine after nasal administration. Drug Test Anal. 2015;7(11-12):1014-1019.
[15] Helsinn Therapeutics. NCT00672074. ClinicalTrials.gov. 2017.
[16] FDA Pharmacy Compounding Advisory Committee. Briefing document. 2024.

---

A grid-indexed literature digest on Ipamorelin — nineteen primary findings, clean GH pulses, and no commercial position on any of them.